CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST NCT00041119

CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST NCT00041119 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Header module
CALGB Protocol Number
Item
CALGB Study No.
integer
C1516238 (UMLS CUI-1)
C2603343 (UMLS CUI-2)
CALGB Patient ID
Item
CALGB Patient ID
text
C1516238 (UMLS CUI-1)
C0030692 (UMLS CUI-2)
Patient's Name
Item
Patient's Name
text
C1299487 (UMLS CUI-1)
ParticipatingGroup
Item
Participating Group
text
C17005 (NCI Thesaurus ObjectClass)
C1257890 (UMLS 2011AA ObjectClass)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
Patient Hospital Number
Item
Patient Hospital Number
integer
C0421459 (UMLS CUI-1)
Participating Group Protocol No.
Item
Participating Group Protocol No.
integer
C0332037 (UMLS CUI-1)
C0237753 (UMLS CUI-2)
Main Member Institution/Adjunct
Item
Main Member Institution/Adjunct
text
C0680022 (UMLS CUI-1)
C2607850 (UMLS CUI-2)
Participating Group Patient No.
Item
Participating Group Patient No.
text
C0687744 (UMLS CUI-1)
C0600091 (UMLS CUI-2)
Item Group
Breast Cancer ELIGIBILITY
Invasive carcinoma of the breast
Item
Histologically confirmed invasive carcinoma of the breast
boolean
C0853879 (UMLS CUI-1)
Radical mastectomy or lumpectomy
Item
Undergone either modified radical mastectomy or lumpectomy
boolean
C0024884 (UMLS CUI-1)
C0740370 (UMLS CUI-2)
Negative tumor margins
Item
Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
boolean
C0332648 (UMLS CUI-1)
No locally advanced breast cancer
Item
No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
boolean
C0006142 (UMLS CUI-1)
C0278601 (UMLS CUI-2)
C0278488 (UMLS CUI-3)
Dermal lymphatics involvement
Item
No involvement of dermal lymphatics on pathology
boolean
C0024235 (UMLS CUI-1)
C0221928 (UMLS CUI-2)
C1314939 (UMLS CUI-3)
High-risk node-negative breast cancer
Item
"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
boolean
C0006142 (UMLS CUI-1)
C0332167 (UMLS CUI-2)
C2371027 (UMLS CUI-3)
Negative sentinel node
Item
Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
boolean
C0796693 (UMLS CUI-1)
C0193867 (UMLS CUI-2)
<= 84 days since last major breast surgery
Item
<= 84 days since last major breast surgery
boolean
C0851312 (UMLS CUI-1)
C3646033 (UMLS CUI-2)
No previous chemotherapy or hormonal therapy
Item
No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
boolean
C3665472 (UMLS CUI-1)
C0279025 (UMLS CUI-2)
Age>=18years
Item
Age >= 18 years
boolean
C0001779 (UMLS CUI-1)
CTC Performance status
Item
CTC Performance status 0-1
boolean
C0027625 (UMLS CUI-1)
C1518965 (UMLS CUI-2)
Non-pregnantandnon-nursing
Item
Non-pregnant and non-nursing
boolean
C0232973 (UMLS CUI-1)
C0006147 (UMLS CUI-2)
No active congestive heart failure
Item
No active congestive heart failure nor myocardial infarction within 6 months prior to registration
boolean
C0018802 (UMLS CUI-1)
C0027051 (UMLS CUI-2)
Disease-free of prior invasive malignancies
Item
Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
boolean
C0242793 (UMLS CUI-1)
C0677898 (UMLS CUI-2)
Willing to stop exogenous hormone therapy
Item
Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
boolean
C0600109 (UMLS CUI-1)
C1516999 (UMLS CUI-2)
C2746065 (UMLS CUI-3)
Discontinued tamoxifen
Item
Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
boolean
C0039286 (UMLS CUI-1)
C1444662 (UMLS CUI-2)
Date tamoxifen started
Item
Date tamoxifen started
date
C25164 (NCI Thesaurus ValueDomain)
C3173309 (UMLS CUI-1)
C0039286 (UMLS CUI-2)
Date tamoxifen discontinued
Item
Date tamoxifen discontinued
date
C25164 (NCI Thesaurus ValueDomain)
C0039286 (UMLS CUI-1)
C2826748 (UMLS CUI-2)
laboratory criteria
Item
Meets ALL of the following laboratory criteria completed within 16 days before registration
boolean
C0022877 (UMLS CUI-1)
C0243161 (UMLS CUI-2)
ANC>=1000/mcL
Item
ANC >= 1000/mcL
boolean
C0948762 (UMLS CUI-1)
C0439378 (UMLS CUI-2)
Date obtained (ANC)
Item
Date obtained (ANC)
date
C25164 (NCI Thesaurus ValueDomain)
C0948762 (UMLS CUI-1)
C1277697 (UMLS CUI-2)
Platelets >= 100,000/mcL
Item
Platelets >= 100,000/mcL
boolean
C0032181 (UMLS CUI-1)
C0439378 (UMLS CUI-2)
Date obtained (Platelets)
Item
Date obtained (Platelets)
date
C25164 (NCI Thesaurus ValueDomain)
C1277697 (UMLS CUI-1)
C0032181 (UMLS CUI-2)
Creatinine <= 2.0 mg/dL
Item
Creatinine <= 2.0 mg/dL
boolean
C0201975 (UMLS CUI-1)
C0439269 (UMLS CUI-2)
Dateobtained(Creatinine)
Item
Date obtained (Creatinine)
date
C25164 (NCI Thesaurus ValueDomain)
C1277697 (UMLS CUI-1)
C0201975 (UMLS CUI-2)
Total Bilirubin
Item
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
boolean
C0201913 (UMLS CUI-1)
C0439269 (UMLS CUI-2)
Date obtained (TotalBilirubin)
Item
Date obtained (Total Bilirubin)
date
C25164 (NCI Thesaurus ValueDomain)
C1277697 (UMLS CUI-1)
C0201913 (UMLS CUI-2)
ULN( Tota lBilirubin)
Item
ULN (Total Bilirubin)
integer
C1519815 (UMLS CUI-1)
C0201913 (UMLS CUI-2)
Item Group
Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial